Hospital

Rachel Rubin, MD, an assistant clinical professor in urology at Georgetown University and a urologic surgeon, discusses whether hypoactive sexual desire disorder is associated with psychological and/or emotional components.

All the participants were in the Beating Lung Cancer in Ohio study, which started before the COVID-19 pandemic.

Niraparib is associated with increased progression-free survival, regardless of the presence or absence of BRCA gene mutations.

Though target medication safety best practices was created with hospitals in mind, community pharmacies can also benefit from these practices.

NVX-CoV2373 (Novavax) was found to provide 100% protection against moderate and severe disease and 90.4% efficacy overall in a phase 3 trial last year.

Sachin Nagrani, MD, the medical director of Heal, discusses Pfizer’s research assessing an Omicron-specific vaccine for adults aged 18 to 55 years.

Adversity has disproportionately hurt certain populations, including essential workers and women, the results of a new analysis show.

The use of these services in oncology is likely here to stay.

The claim is based on requested exemption from administering immunizations because of "needle phobia."

Rachel Rubin, MD, an assistant clinical professor in urology at Georgetown and a urologic surgeon, discusses hypoactive sexual desire disorder and the current treatments available for this medical condition.

Ronald T. Piervincenzi, CEO of US Pharmacopeia, discusses how building resilience in the medicine supply chain will help bolster preparedness for what may arise during the COVID-19 pandemic and beyond.

This Valentine’s Day, pharmacists can remind patients that they may not need to feel guilty when they indulge in a small piece of chocolate.

Bebtelovimab gets Emergency Use Authorization to treat mild-to-moderate COVID-19 in adults and pediatric patients who are at high risk for progression to severe COVID-19.

Ronald T. Piervincenzi, CEO of US Pharmacopeia, discusses contributing factors leading to health care professionals experience of an erosion of trust in the medicine supply chain.

Tiago Reis Marques, MD, PhD, CEO of Pasithea Therapeutics, discusses the future of ketamine and psychedelic medicines in the treatment of mental health and brain disorders.

The drug's novel molecular structure may result in fewer toxic adverse effects.

American Heart Month is another example of the essential and valuable position that pharmacists hold in improving health care outcomes and optimizing patient-centered care.

Ronald T. Piervincenzi, CEO of US Pharmacopeia, discusses how drug shortages are related to medicine quality issues.

Study shows that 98% of cases of multi-system inflammatory syndrome in children (MIS-C) were unvaccinated, suggesting that vaccination reduces the chance of a child who had COVID-19 later developing MIS-C.

The lingering effects of the COVID-19 pandemic, including supply concerns and staffing shortages, have made technological solutions become more crucial.

Ronald T. Piervincenzi, CEO of US Pharmacopeia (USP), discusses recent survey data demonstrating 90% of physicians had experienced an erosion of trust in the US supply chain’s ability to deliver safe, quality medicines.

Edoxaban (Savaysa) can reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.

Tiago Reis Marques, MD, PhD, CEO of Pasithea Therapeutics, addresses how pharmacists can respond to questions patients may ask them about ketamine and other psychedelic treatments.

Tiago Reis Marques, MD, PhD, CEO of Pasithea Therapeutics, explains how ketamine infusions work when administered in patients’ homes and what safety precautions would be taken by providers in this setting.

A variety of drugs from several medication classes are under investigation.

New composite pharmacy adherence measure is a major step in developing standard pharmacy performance measures focused on improving patient care.

Study shows that treatment with rituximab (Rituxan) for B-cell non-Hodgkin lymphoma prior to COVID-19 vaccination significantly lowered the number of patients who developed blocking antibodies for the virus.

Lack of immediate results, cultural barriers, and high costs lead many to gamble with their cardiovascular health, study results show.

The calculation instrument displayed good discrimination, with a C-index of 0.72, as well as good calibration, investigators say.

Data suggest that omicron-specific CD8-positive T cell responses were more than 80% cross-reactive with the CD8-positive T cell response to the original strain of the virus.